RBFC
HRMY icon

Roman Butler Fullerton & Co’s Harmony Biosciences HRMY Stock Holding History

Roman Butler Fullerton & Co’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,494
Closed -$885K – 177
2022
Q2 		$885K Buy
+16,494
New +$743K 0.49% 66

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Roman Butler Fullerton & Co's HRMY Position: Q3 2022 in Review

Roman Butler Fullerton & Co sold out of Harmony Biosciences (HRMY) in Q3 2022, closing a stake of 16,494 shares — an estimated $885K sold.

Roman Butler Fullerton & Co first reported a position in HRMY in Q2 2022 and held it in 1 quarter. The position peaked at $885K in Q2 2022. 203 funds tracked by Wall St. Rank hold HRMY as of Q3 2022.

  • Roman Butler Fullerton & Co reported no remaining Harmony Biosciences position as of Q3 2022 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 16,494 Harmony Biosciences shares in Q3 2022, an estimated $885K.
  • Roman Butler Fullerton & Co first reported a position in Harmony Biosciences in Q2 2022 and held it in 1 quarter.
  • Roman Butler Fullerton & Co's Harmony Biosciences position peaked at $885K in Q2 2022.
  • 203 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2022.

Based on Roman Butler Fullerton & Co's 13F filing for Q3 2022, filed 17 Oct 2022.